Charles Brenner, PhD, director of the Obesity Initiative at the University of Iowa, discusses properties of nicotinamide riboside that have been uncovered since its initial discovery in 2004.
She talks about evaluating obesity medications, her tips for choosing the right medication for the right patient, and medications that are on the horizon. This is also the topic of her session at our...
Dr Harrison discusses the prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis in the United States, the correlation between NAFLD and obesity, and more.
In this podcast, Dr Bruce Lee from the Global Obesity Prevention Center at Johns Hopkins talks about the many contributing factors to childhood obesity as well as possible solutions to the growing...
Bruce Y. Lee, MD, from the Global Obesity Prevention Center at Johns Hopkins, explains what a systems approach is, how you can use them to better manage your patients' cardiometabolic health...
Andrea Richardson, from RAND Corporation, discusses her research on obesity and environmental health. Which environmental interventions are the most successful?
Considering pharmacotherapy for your patient with obesity? Here’s what you should know, according to Harold Bays, MD, who presented “Current and Future of Obesity Drug Therapies: Echoes of Today’s Metabolic...
<p>Obesity is an epidemic. How can providers better care for their patients with obesity and comorbidities?&nbsp;Sharon Fruh, FNP, sheds light and discusses her latest article on...
<p>There are currently 6 pharamacotherapies for obesity, but are they being prescribed enough? Dr Angela Golden, who is a nurse practitioner and owner of NP From Home, answers that question and...
Nearly half of patients with obesity also have depression, according to the CDC. In this Q&A, Leslie Heinberg, PhD, from Cleveland Clinic, discusses the association between depression and obesity, and...
